Therma Bright Inc Announced The Submission Of Its Health Canada Application For The Smart-Enabled Acuvid Covid-19 Rapid Antigen Saliva Test For Point-Of-Care Use (Poc). The Hc Application Includes All The Updated Data From The Company'S Us Food And Drug Administration'S Emergency Use Authorization (Eua) Application."We'Re Excited With Our Acuvid Health Canada Application And The Prospect Of Approval For Our Unique Covid-19 Rapid Antigen Saliva Test For Point-Of-Care (Poc)," Shared Rob Fia, Ceo Of Therma Bright. "While We Wait For Both The Us Fda Emergency Use Authorization (Eua) And Health Canada Review And Approval, Our Team Has Begun Preparing Other Regulatory Applications Where We Believe Our Acuvid Covid-19 Rapid Antigen Saliva Test Will Be In High Demand This Fall When Countries From Around The Globe Expect A Resurgence Of Covid-19."Therma Bright Is Not Making Any Express Or Implied Claims That Its Test Product Has The Ability To Eliminate Or Cure Covid-19 Or The Sars-Cov-2 Virus.Therma Bright, Developer Of The Smart-Enabled Acuvid Covid-19 Rapid Antigen Saliva Test, Is A Progressive Medical Diagnostic And Device Technology Company Focused On Providing Consumers And Medical Professionals With Quality, Innovative Solutions That Address Some Of Today'S Most Important Medical And Healthcare Challenges.
